Last reviewed: June 8, 2026
Last updated: June 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
The FDA has not issued orders to discontinue compounded semaglutide, though regulatory scrutiny of GLP-1 compounding has increased following shortages of brand-name Ozempic and Wegovy. PlexusDx sources all semaglutide from licensed 503A compounding pharmacies and maintains compliance with current federal pharmacy regulations. Understanding the current landscape helps patients make informed decisions about their weight loss treatment options.
Current Regulatory Status of Compounded Semaglutide
Semaglutide compounding remains lawful under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits licensed pharmacies to compound medications when patient need exists and supply constraints occur. The FDA has not published guidance to halt semaglutide compounding, and no federal mandate prohibits its manufacture or distribution. However, the agency continues monitoring compounding quality, ingredient sourcing, and pharmacy licensing to ensure public safety.
PlexusDx partners exclusively with licensed 503A compounding pharmacies that maintain state board oversight, pharmacy technician certification, and quality control protocols. These facilities undergo routine inspections and must document their raw material sourcing and sterility testing. This regulatory framework distinguishes legitimate compounding operations from unlicensed alternatives that operate outside federal oversight.
Why FDA Scrutiny Has Increased on GLP-1 Compounding
Between 2022 and 2024, severe shortages of brand-name semaglutide and tirzepatide created demand that legitimate pharmacies struggled to meet. This gap attracted unlicensed operations offering compounded versions without proper sterility assurance, contamination testing, or dosing accuracy. The FDA has issued warning letters to specific compounding facilities operating outside 503A regulations, not to the compounding model itself.
Media reports have conflated enforcement actions against rogue compounders with potential bans on all compounded GLP-1 medications. In reality, regulatory pressure targets facilities lacking proper licensing, ingredient verification, or quality assurance—not the compounding pathway itself. PlexusDx maintains transparency about its pharmacy partners' compliance history and licensing status.
How PlexusDx Ensures Long-Term Access and Affordability
PlexusDx sources compounded semaglutide injection at a flat rate of $149 per month, with no membership fees, insurance requirements, or flat per-compound pricing increases. This pricing model ensures patients beginning treatment at lower doses pay the same monthly cost as those optimizing at higher maintenance doses. The company's commitment to affordability reflects confidence in the regulatory stability of 503A compounding.
As brand-name GLP-1 medications face ongoing supply constraints and rising list prices, compounded alternatives remain critical for patient access. PlexusDx serves all 50 states and accepts HSA and FSA funds, creating multiple pathways for cost management. The company's expansion of product offerings—including oral semaglutide, tirzepatide injection and oral forms, and dual-compound GLP-Squared—signals investment in sustained market presence.
The Role of Genetic Testing in Personalizing Your GLP-1 Choice
Individual response to GLP-1 medications varies based on genetic variants in appetite-regulation pathways. PlexusDx offers the Precision Peptide Genetic Test, which maps 14 metabolic pathways and identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence medication efficacy and side-effect risk. This personalized insight helps patients select compounded semaglutide, tirzepatide, or dual-compound formulations optimized for their genetic profile.
Knowing your peptide-pathway genetics removes guesswork from GLP-1 selection and dosing. Patients with specific GLP1R variants may experience faster satiety on lower doses, while others may require higher maintenance levels to achieve target weight loss. PlexusDx adds the Precision Peptide Genetic Test at $99 after the first month of treatment, enabling data-driven decisions about which compounded medication best matches your biology.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Will the FDA ban compounded semaglutide?
No federal ban on 503A compounded semaglutide exists, and the FDA has not announced plans to issue one. The agency continues to enforce standards against unlicensed compounders but supports legitimate 503A operations that meet sterility and sourcing requirements. PlexusDx works exclusively with licensed, inspected compounding pharmacies.
How does compounded semaglutide compare to brand-name Ozempic in efficacy?
Compounded semaglutide contains the same active pharmaceutical ingredient as Ozempic and achieves identical metabolic effects at equivalent doses. Clinical outcomes depend on dose titration, adherence, and individual genetic factors—not the brand or compounded source. PlexusDx's Precision Peptide Genetic Test identifies your optimal medication and dose target based on peptide-pathway genetics.
What if compounding becomes unavailable—will PlexusDx patients be left without treatment?
PlexusDx maintains partnerships across multiple licensed 503A compounding networks and actively monitors regulatory developments. Even if compounding faced restrictions, the company's product portfolio includes oral semaglutide and tirzepatide options that preserve patient access. Current regulatory trends do not support an imminent ban.
Are compounded medications safe and sterile?
Licensed 503A compounding pharmacies must meet rigorous USP standards for sterility testing, contamination prevention, and ingredient sourcing verification. Unlicensed operations pose genuine safety risks, but legitimate compounders undergo state board inspection and maintain quality documentation. PlexusDx partners only with verified, compliant facilities.
How does the Precision Peptide Genetic Test help me choose between semaglutide and tirzepatide?
The test identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence your response to specific GLP-1 pathways. Patients with certain genetic profiles may experience superior weight loss or fewer side effects on tirzepatide's dual-agonist mechanism versus semaglutide's single-agonist action. At $99 after your first treatment month, the test provides personalized guidance for optimizing your compounded medication selection.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Sustaining Progress: Can You Stay on a Low Dose of Tirzepatide for Weight Management?
How Long After Injecting Ozempic Do You Feel It?